Clinical Trial Update: Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update comparing ipilimumab to high-dose interferon alfa-2b in patients with resected high-risk Stage III–IV melanoma; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma Ajcc V6 and V7
• Melanoma
• Melanoma of Unknown Primary
• Stage Iiib Cutaneous Melanoma Ajcc V7
• Stage Iiic Cutaneous Melanoma Ajcc V7

Drugs mentioned

• Intron A (interferon alfa-2b) (interferon alfa-2b)
• ipilimumab (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma of Unknown Primary, Recurrent Melanoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-05-27